NeoGenomics Raises 2026 Revenue Guidance to $807 Million-$809 Million
- NeoGenomics raised its 2026 revenue forecast on October 28 to $807 million-$809 million from $802 million-$806 million.
- Adjusted EBITDA guidance increased to about $60 million from $56 million-$58 million, implying roughly 38% annual growth.
- The outlook assumes low-teens clinical revenue growth, with next-generation sequencing revenue expected to rise more than 25%.
- Adjusted gross margin is expected to expand by more than 150 basis points for the full year.
- Third-quarter revenue rose 11% to $209 million; adjusted EBITDA increased 53% to $19 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.